Study guide

2.4 Host Immune Response to Infection and Immunopathology

Board Certified Infectious Diseases Pharmacist BCIDP

Track your progress as you read

Finished sections get a check mark.

1 Causes of Infectious Diseases

1.1 Bacterial Pathogens: Gram-Positive, Gram-Negative, and Atypical Organisms 1.2 Viral Pathogens: Respiratory, Herpesviruses, Hepatitis, and Emerging Viruses 1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi 1.4 Parasitic and Vector-Borne Pathogens: Protozoa and Helminths

2 Microbiology Diagnostics, Resistance & Host Response

2.1 Diagnostic Microbiology: Phenotypic, Molecular, and Rapid Diagnostic Methods 2.2 Molecular Mechanisms of Antimicrobial Resistance 2.3 Microbial Virulence Factors, Toxins, and Biofilm Dynamics 2.4 Host Immune Response to Infection and Immunopathology

3 Clinical Assessment & Diagnostic Evaluation

3.1 Clinical Assessment, Infection Screening, and Severity Stratification 3.2 Diagnostic Biomarkers and Clinical Laboratory Interpretation 3.3 Social Determinants of Health and Disparities in Infectious Diseases

4 Pharmacokinetics, Pharmacodynamics & Special Populations

4.1 Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials 4.2 Host and Environmental Risk Factors for Infection 4.3 Antimicrobial Dosing and Considerations in Special Populations

5 Respiratory and Skin/Soft Tissue Infections

5.1 Pharmacotherapy of Upper and Lower Respiratory Tract Infections 5.2 Pharmacotherapy of Skin and Soft Tissue Infections

6 Cardiovascular, Bone, and Joint Infections

6.1 Pharmacotherapy of Infective Endocarditis and CIED Infections 6.2 Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI

7 Central Nervous System and Abdominal Infections

7.1 Pharmacotherapy of Central Nervous System Infections 7.2 Pharmacotherapy of Intra-abdominal, Hepatic, and GI Infections

8 Urologic, Gynecologic, and Sexually Transmitted Infections

8.1 Pharmacotherapy of Urinary Tract and Gynecologic Infections 8.2 Pharmacotherapy of Sexually Transmitted Infections

9 HIV Infection and Opportunistic Infections

9.1 Antiretroviral Therapy and Management of HIV-1 Infection 9.2 Prophylaxis and Management of HIV-Associated Opportunistic Infections

10 Infections in Immunocompromised Hosts and Complex Syndromes

10.1 Infections in Solid Organ Transplant and Hematologic Malignancy 10.2 Sepsis, Septic Shock, and Systemic Complications

11 Medication Administration and Adjunctive Therapies

11.1 Antimicrobial Administration, Vascular Access, and Stability 11.2 Adjunctive Pharmacotherapies and Supportive Care in Serious Infections 11.3 Assessment of Therapeutic Outcomes and Infection Failure

12 Therapeutic Drug Monitoring, Toxicity, and De-escalation

12.1 Therapeutic Drug Monitoring and Precision Pharmacokinetics 12.2 Antimicrobial Adverse Drug Events and High-Risk Drug Interactions 12.3 Antimicrobial De-escalation and IV-to-Oral Transition Strategies

13 Care Transitions, Patient Counseling & Travel Medicine

13.1 Outpatient Parenteral and Complex Oral Antimicrobial Therapy (OPAT/COPAT) 13.2 Patient and Caregiver Counseling, Education, and Adherence 13.3 Travel Medicine, Immunizations, and Prophylactic Regimens

14 Antimicrobial Stewardship Operations, Metrics & Resistance

14.1 Antimicrobial Stewardship Core Elements and Regulatory Mandates 14.2 Stewardship Metrics: Days of Therapy (DOT), DDD, and SAAR 14.3 Surveillance and Tracking of Antimicrobial Resistance Patterns 14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis

15 Formulary Management, Infection Prevention & Population Health

15.1 Antimicrobial Formulary Management and Restriction Strategies 15.2 Public Health, Disease Reporting, and Adult Immunization Strategies 15.3 Healthcare Infection Prevention and Environmental Transmission

16 Literature Evaluation, Informatics & Quality Improvement

16.1 Infectious Diseases Information Resources, Databases, and Clinical Guidelines 16.2 Critical Literature Evaluation and Biostatistical Interpretation 16.3 Quality Improvement Methodologies and Medication Safety in ID 16.4 Clinical Informatics, Decision Support Systems, and Automated Alerts

2.4 Host Immune Response to Infection and Immunopathology

Key Takeaways Explain This Topic AI

Innate immune recognition of pathogen-associated molecular patterns (PAMPs) relies upon Toll-like receptors (TLRs) and the complement cascade to trigger immediate defensive inflammation.

Deficiencies in terminal complement pathway components (C5 through C9) or therapeutic blockade with eculizumab/ravulizumab confer an extreme, specific susceptibility to invasive Neisseria infections.

The depth and duration of neutropenia dictate opportunistic infection risk: severe neutropenia (ANC < 500 cells/mm3) predisposes to bacterial pathogens, while prolonged profound neutropenia (>7 days at ANC < 100 cells/mm3) dramatically elevates the risk of angioinvasive filamentous fungal infections.

Defects in cell-mediated immunity primarily impair macrophage activation and phagolysosome maturation, predisposing to intracellular pathogens including Listeria, Cryptococcus, Histoplasma, and Pneumocystis jirovecii.

Sepsis immunopathology follows a dynamic biphasic course transitioning from an early hyper-inflammatory cytokine storm into a compensatory anti-inflammatory response syndrome (CARS) marked by immune exhaustion.

Last updated: October 2026

Host Immune Response to Infection and Immunopathology

The human immune response to microbial invasion is an integrated system comprising innate physical barriers, cellular and humoral effectors, and antigen-specific adaptive immunity. Disruption of these defensive components creates predictable susceptibilities to specific opportunistic pathogens. Mastering immunopathology allows the specialist to correlate host immune deficits with microbiological risks, direct appropriate prophylactic regimens, and manage dysregulated immune responses.

Innate Immunity and Pattern Recognition Receptors

Innate immunity provides non-specific host protection within minutes of microbial contact. Recognition depends upon germline-encoded Pattern Recognition Receptors (PRRs) that detect invariant molecular motifs unique to microbes, termed Pathogen-Associated Molecular Patterns (PAMPs) , or host cellular stress molecules, termed Damage-Associated Molecular Patterns (DAMPs) .

Toll-Like Receptors (TLRs)

TLRs are transmembrane glycoproteins situated on cell surfaces or endosomal compartments of dendritic cells, macrophages, and neutrophils:

TLR4 (with MD-2 and CD14): Recognizes Lipid A of Gram-negative lipopolysaccharide (LPS).

TLR2 (heterodimerized with TLR1 or TLR6): Recognizes Gram-positive peptidoglycan, lipoteichoic acid, and mycobacterial lipoarabinomannan.

TLR5: Recognizes bacterial flagellin.

Endosomal TLRs (TLR3, TLR7, TLR8, TLR9): Sense microbial nucleic acids; TLR3 recognizes viral double-stranded RNA (dsRNA), TLR7/8 recognizes single-stranded RNA (ssRNA), and TLR9 detects unmethylated cytidine-phosphate-guanosine (CpG) DNA motifs characteristic of bacteria and DNA viruses.

Binding of PAMPs to TLRs recruits adaptor proteins (MyD88 or TRIF), activating downstream kinases that phosphorylate I κ \kappa κ B. This liberates nuclear factor kappa B ( NF- κ \kappa κ B ) and activates mitogen-activated protein kinases (MAPK) and interferon regulatory factors (IRFs), driving gene transcription of pro-inflammatory cytokines (TNF- α \alpha α , IL- 1 β 1\beta 1 β , IL-6), chemokines (IL-8), and Type I interferons (IFN- α \alpha α , IFN- β \beta β ).

The Complement Cascade

The complement system comprises circulating plasma proteins that function in an enzymatic activation cascade. Classical Pathway Lectin Pathway Alternative Pathway

  • (Ab-Ag Complexes: IgG/IgM) (MBL / Ficolins -> Mannose) (Spontaneous C3 Tickover)
  • │ │ │
  • ▼ ▼ ▼
  • C1qrs MASPs Factor B & D
  • │ │ │
  • └─────────────────► C4b2a ◄──────┘ ▼
  • (C3 Convertase) C3bBb
  • │ │
  • └──────────────┬────────────────┘
  • ▼

Cleaves C3 into:

  • │
  • ┌──────────────┴──────────────┐
  • ▼ ▼
  • C3a (Anaphylatoxin) C3b (Potent Opsonin)
  • │
  • ▼
  • C5 Convertase
  • (C4b2a3b / C3bBbC3b)
  • │
  • ┌──────────────┴──────────────┐
  • ▼ ▼
  • C5a (Chemotaxin) C5b
  • │
  • ▼ + C6, C7, C8, poly-C9
  • ┌─────────────────┐
  • │ MAC (C5b-9) │
  • │ Direct Lysis │
  • └─────────────────┘
  • Complement Pathways and Key Mediators

Activation Pathways:

Classical Pathway: Triggered by antibody-antigen complexes binding C1q (IgM is most potent; IgG1 and IgG3 are active).

Lectin Pathway: Mannose-binding lectin (MBL) binds terminal mannose sugars on microbial surfaces, activating MBL-associated serine proteases (MASPs).

Alternative Pathway: Continuously active at low levels via spontaneous hydrolysis ("tickover") of C3 to C 3 ( H 2 O ) C3(H_2O) C 3 ( H 2 ​ O ) , which binds Factor B and Factor D to form fluid-phase C3 convertase.

Critical Cleavage Products:

C3b: Major opsonin that covalently tags microbial surfaces, engaging complement receptor 1 (CR1, CD35) on neutrophils and macrophages to accelerate phagocytosis.

C3a and C5a (Anaphylatoxins): Trigger mast cell degranulation, smooth muscle contraction, and marked vascular permeability.

C5a (Chemotactic Factor): Potent chemoattractant that directs neutrophils to the focus of infection.

Membrane Attack Complex (MAC, C5b-9): C5b recruits C6, C7, C8, and 12–18 molecules of C9 to polymerize a hydrophobic, transmembrane lytic pore (10 nm diameter) across the lipid bilayer of target cells.

Clinical Complement Deficiencies

Early Classical Pathway (C1, C4, C2) Deficiencies: Impair immune-complex clearance, predisposing to systemic lupus erythematosus (SLE) and recurrent pyogenic infections caused by encapsulated bacteria ( S. pneumoniae , H. influenzae ).

C3 Deficiency: Severe, life-threatening susceptibility to recurrent pyogenic infections and encapsulated bacteria, as C3 is the central junction of all three pathways.

Terminal Pathway (C5, C6, C7, C8, C9) Deficiencies: Specifically impair formation of the Membrane Attack Complex. Gram-positive organisms resist MAC lysis because of their thick peptidoglycan wall, but Gram-negative Neisseria species rely upon direct MAC lytic pores for killing. Terminal deficiencies confer a 1,000- to 10,000-fold increased lifetime risk of invasive meningococcal disease ( Neisseria meningitidis ) and disseminated gonococcal infection ( Neisseria gonorrhoeae ).

Therapeutic C5 Blockade (Eculizumab, Ravulizumab): Humanized monoclonal antibodies that bind C5 and prevent cleavage into C5a and C5b, blocking MAC assembly to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Patients receive mandatory meningococcal vaccination (MenACWY conjugate and MenB vaccines) along with daily oral penicillin or macrolide antimicrobial prophylaxis throughout the duration of therapy.

Neutrophil Kinetics and Phagocytic Killing

Polymorphonuclear neutrophils (PMNs) represent the primary cellular defense against acute bacterial and fungal infections.

Absolute Neutrophil Count (ANC) Stratification

ANC ( cells/mm 3 ) = Total WBC (cells/ μ L) × ( % Segmented Neutrophils + % Band Neutrophils 100 ) \text{ANC} (\text{cells/mm}^3) = \text{Total WBC (cells/}\mu\text{L)} \times \left( \frac{\% \text{Segmented Neutrophils} + \% \text{Band Neutrophils}}{100} \right) ANC ( cells/mm 3 ) = Total WBC (cells/ μ L) × ( 100 % Segmented Neutrophils + % Band Neutrophils ​ )

Stratification Category Absolute Neutrophil Count (ANC) Clinical Infection Vulnerabilities

Normal Range 1,500 – 8,000 cells/mm 3 ^3 3 Baseline immune competency.

Mild Neutropenia 1,000 – 1,499 cells/mm 3 ^3 3 Minimal risk of spontaneous opportunistic infections.

Moderate Neutropenia 500 – 999 cells/mm 3 ^3 3 Moderate increase in infection risk; requires close observation during myelosuppressive therapy.

Severe Neutropenia < 500 cells/mm 3 ^3 3 High risk of acute bacteremic infection. Mandates empiric broad-spectrum anti-pseudomonal coverage (e.g., cefepime, piperacillin-tazobactam, meropenem) for any temperature ≥ 38.3 ∘ C \ge 38.3^\circ\text{C} ≥ 38. 3 ∘ C ( 101 ∘ F 101^\circ\text{F} 10 1 ∘ F ) or ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C over 1 hour.

Profound Neutropenia < 100 cells/mm 3 ^3 3 Extreme susceptibility. If prolonged (>7 days), patient faces high risk for invasive filamentous mold infections ( Aspergillus , Fusarium , Mucorales ) and endogenous gut-derived bacteremia.

Respiratory Burst and Chronic Granulomatous Disease

Upon phagocytosis, the pathogen is internalized within a phagosome that fuses with primary and secondary lysosomes. Neutrophils then assemble the multi-protein NADPH oxidase enzyme complex (comprising membrane subunits gp91phox, p22phox and cytosolic subunits p47phox, p67phox, p40phox, and Rac2) at the phagolysosomal membrane.

NADPH + 2 O 2 → NADPH Oxidase NADP + + H + + 2 O 2 ∙ − ( Superoxide ) \text{NADPH} + 2\text{O}_2 \xrightarrow{\text{NADPH Oxidase}} \text{NADP}^+ + \text{H}^+ + 2\text{O}_2^{\bullet -} \quad (\text{Superoxide}) NADPH + 2 O 2 ​ NADPH Oxidase ​ NADP + + H + + 2 O 2 ∙− ​ ( Superoxide ) 2 O 2 ∙ − + 2 H + → Superoxide Dismutase H 2 O 2 + O 2 ( Hydrogen Peroxide ) 2\text{O}_2^{\bullet -} + 2\text{H}^+ \xrightarrow{\text{Superoxide Dismutase}} \text{H}_2\text{O}_2 + \text{O}_2 \quad (\text{Hydrogen Peroxide}) 2 O 2 ∙− ​ + 2 H + Superoxide Dismutase ​ H 2 ​ O 2 ​ + O 2 ​ ( Hydrogen Peroxide ) H 2 O 2 + Cl − → Myeloperoxidase (MPO) HOCl + OH − ( Hypochlorous Acid ) \text{H}_2\text{O}_2 + \text{Cl}^- \xrightarrow{\text{Myeloperoxidase (MPO)}} \text{HOCl} + \text{OH}^- \quad (\text{Hypochlorous Acid}) H 2 ​ O 2 ​ + Cl − Myeloperoxidase (MPO) ​ HOCl + OH − ( Hypochlorous Acid )

Chronic Granulomatous Disease (CGD): An inborn error of immunity caused by mutations in NADPH oxidase subunits (X-linked gp91phox deficiency accounts for ~65% of cases). Neutrophils can engulf microbes normally but cannot generate superoxide or hydrogen peroxide.

Catalase-Negative Pathogens: Microbes such as Streptococcus pneumoniae produce endogenous H 2 O 2 \text{H}_2\text{O}_2 H 2 ​ O 2 ​ as a metabolic byproduct. Because they lack catalase, this hydrogen peroxide accumulates in the phagolysosome and is weaponized by host myeloperoxidase to kill the bacteria.

Catalase-Positive Pathogens: Pathogens producing catalase degrade their endogenous hydrogen peroxide ( 2 H 2 O 2 → 2 H 2 O + O 2 2\text{H}_2\text{O}_2 \to 2\text{H}_2\text{O} + \text{O}_2 2 H 2 ​ O 2 ​ → 2 H 2 ​ O + O 2 ​ ), leaving the neutrophil without oxidative killing capacity. Patients with CGD suffer recurrent life-threatening infections caused by five hallmark catalase-positive organisms:

  • Staphylococcus aureus
  • Burkholderia cepacia complex
  • Serratia marcescens
  • Nocardia species
  • Aspergillus species

Management: Lifelong antibacterial prophylaxis with trimethoprim-sulfamethoxazole, antifungal prophylaxis with itraconazole or voriconazole, and subcutaneous recombinant interferon-gamma (IFN- γ \gamma γ ).

Adaptive Immunity: Humoral vs. Cell-Mediated

Adaptive immunity provides targeted, clonal pathogen destruction and lasting immunological memory, segregated into humoral (B-cell) and cell-mediated (T-cell) arms.

Comparative Features of Adaptive Immune Deficiencies

Immune Arm Key Cells and Mediators Associated Conditions and Risk Factors Pathogen Predisposition and Clinical Prophylaxis

Humoral Immunity B lymphocytes, plasma cells; immunoglobulins (IgM, IgG, IgA, IgE) Common variable immunodeficiency (CVID), X-linked agammaglobulinemia, multiple myeloma, CLL, anti-CD20 therapy (rituximab), anatomical/functional asplenia Encapsulated bacteria: S. pneumoniae , H. influenzae type b, N. meningitidis . Also enteroviruses and Giardia duodenalis . Management: Immunoglobulin replacement (IVIG/SCIG); vaccination schedules; post-splenectomy amoxicillin-clavulanate for acute fever

Cell-Mediated Immunity (CMI) CD4+ T-helper cells (Th1, Th2, Th17), CD8+ cytotoxic T lymphocytes (CTLs); IFN- γ \gamma γ , IL-2, IL-12 Advanced HIV infection (CD4 < 200 cells/ μ \mu μ L), solid organ transplant (calcineurin inhibitors [tacrolimus, cyclosporine]), high-dose corticosteroids, purine analogs (fludarabine) Intracellular bacteria: Listeria monocytogenes , Mycobacterium tuberculosis , NTM, Salmonella , Legionella . Fungi: Pneumocystis jirovecii , Cryptococcus neoformans , Histoplasma , Coccidioides . Viruses: CMV, HSV, VZV, EBV, HHV-8. Parasites: Toxoplasma gondii , Strongyloides . Prophylaxis: TMP-SMX, valganciclovir

Note

The spleen contains specialized marginal zone macrophages and marginal zone B-cells essential for filtering blood-borne bacteria and generating rapid IgM responses against bacterial polysaccharides. Asplenic patients face high risk for Overwhelming Post-Splenectomy Infection (OPSI)—a fulminant sepsis with rapid progression to shock and DIC, most commonly triggered by Streptococcus pneumoniae .

Sepsis Immunopathology: Cytokine Storms to CARS

Sepsis is defined clinically as life-threatening organ dysfunction caused by a dysregulated host response to infection (Sepsis-3). Rather than pure unbridled inflammation, sepsis follows a dynamic, biphasic immunopathological trajectory. Infection Onset

  • │
  • ▼
  • ┌────────────────────────────────────────────────────────┐
  • │ Early Hyper-Inflammatory Phase ("Cytokine Storm") │
  • │ - Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-12 │
  • │ - Massive endothelial injury, glycocalyx shedding │
  • │ - Disseminated intravascular coagulation (DIC) │
  • │ - Capillary leak, vasodilation, distributive shock │
  • └───────────────────────────┬────────────────────────────┘
  • │
  • ▼
  • ┌────────────────────────────────────────────────────────┐
  • │ Compensatory Anti-Inflammatory Response Syndrome (CARS)│
  • │ - Anti-inflammatory cytokines: IL-10, TGF-β, sTNFR │
  • │ - Marked apoptosis of CD4+ T-cells, B-cells, dendrites │
  • │ - Downregulation of monocytic HLA-DR expression │
  • │ - Upregulation of checkpoint inhibitors (PD-1 / PD-L1) │
  • │ - Secondary ICU nosocomial infections, CMV reactivation │
  • └────────────────────────────────────────────────────────┘

Early Hyper-Inflammatory Phase: Massive stimulation of PRRs triggers uncontrolled release of early-phase mediators ( TNF- α \alpha α and IL- 1 β 1\beta 1 β ), followed by systemic amplification via IL-6 . These cytokines disrupt the endothelial glycocalyx, activate the tissue factor clotting pathway, impair protein C anticoagulant mechanisms, and cause diffuse microvascular thrombosis, tissue hypoperfusion, and lactic acidosis.

Compensatory Anti-inflammatory Response Syndrome (CARS): Occurs concurrently and sequentially to suppress systemic inflammation. Sustained anti-inflammatory signaling driven by IL-10 and transforming growth factor-beta ( TGF- β \beta β ) suppresses monocyte human leukocyte antigen-DR (HLA-DR) expression (<30% expression indicates severe immunoparalysis). Apoptosis of CD4+ T-cells, B-cells, and dendritic cells leaves patients profoundly immunosuppressed, predisposing ICU patients to secondary nosocomial infections ( P. aeruginosa , Acinetobacter , Enterobacterales ), opportunistic fungal infections ( Candida , Aspergillus ), and viral reactivation (CMV, EBV).